ResearcherFred and Pamela Buffett Cancer CenterNo recent work listed

Hannah M. King

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3449-5844; OpenAlex author ID A5103273716. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper

Papers 3

Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Co-author DOI 10.1016/j.bmcl.2021.128061 ↗
HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. Co-author DOI 10.1016/j.yexcr.2020.111960 ↗
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Co-author DOI 10.1124/mol.119.116855 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Amarnath (Amar) Natarajan · 2 shared papers, 2019–2021 · strength 0.20
- Paper Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. DOI 10.1016/j.bmcl.2021.128061 ↗
- Paper CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. DOI 10.1124/mol.119.116855 ↗
H. Carlo Maurer · 1 shared paper, 2020 · strength 0.13
- Paper HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. DOI 10.1016/j.yexcr.2020.111960 ↗
Bailee H. Sliker · 1 shared paper, 2020 · strength 0.13
- Paper HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. DOI 10.1016/j.yexcr.2020.111960 ↗
Joyce C. Solheim · 1 shared paper, 2020 · strength 0.13
- Paper HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. DOI 10.1016/j.yexcr.2020.111960 ↗
Kenneth P. Olive · 1 shared paper, 2020 · strength 0.13
- Paper HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. DOI 10.1016/j.yexcr.2020.111960 ↗
Nicholas Taylor Woods · 1 shared paper, 2021 · strength 0.12
- Paper Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. DOI 10.1016/j.bmcl.2021.128061 ↗
Henry C.-H. Law · 1 shared paper, 2021 · strength 0.12
- Paper Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. DOI 10.1016/j.bmcl.2021.128061 ↗
Smit Kour · 1 shared paper, 2019 · strength 0.08
- Paper CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. DOI 10.1124/mol.119.116855 ↗
Michael Anthony Hollingsworth · 1 shared paper, 2019 · strength 0.08
- Paper CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. DOI 10.1124/mol.119.116855 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.